News | August 10, 2024
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Subscribe To Our Newsletter & Stay Updated
